Home use of an artificial beta cell in type 1 diabetes

New England Journal of Medicine

Volumn 373, Issue 22, 2015, Pages 2129-2140

  Thabit, H ^a,b   Tauschmann, M ^a   Allen, J M ^a   Leelarathna, L ^a,b   Hartnell, S ^b   Wilinska, M E ^a   Acerini, C L ^a   Dellweg, S ^f   Benesch, C ^f   Heinemann, L ^f   Mader, J K ^g   Holzer, M ^g   Kojzar, H ^g   Exall, J ^c   Yong, J ^c   Pichierri, J ^d   Barnard, K D ^e   Kollman, C ^h   Cheng, P ^h   Hindmarsh, P C ^d   Campbell, F M ^c   Arnolds, S ^f   Pieber, T R ^g   Evans, M L ^a,b   Dunger, D B ^a   Hovorka, R ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Leeds Children's Hospital   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e BOURNEMOUTH UNIVERSITY   (United Kingdom)

^f Profil   (Germany)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; ANTIDIABETIC AGENT; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLOSED LOOP SYSTEM; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOME CARE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SENSOR; SENSOR AUGMENTED PUMP THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADVERSE EFFECTS; ALGORITHM; BLOOD; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; INFUSION PUMP; INSULIN INFUSION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALGORITHMS; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED;

EID: 84946427627     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1509351     Document Type: Article

References (29)

1. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-76.
2. Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013; 36: 2035-7.
3. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: An international comparison. Diabet Med 2015; 32: 1036-50.
4. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997; 20: 22-5.
5. Johnson SR, Cooper MN, Davis EA, Jones TW. Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents. Diabet Med 2013; 30: 1126-31.
6. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-76.
7. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805.
8. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-32.
9. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011; 7: 385-95.
10. Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012; 61: 2230-7.
11. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-Logic Artificial Pancreas System: A pilot study in adults with type 1 diabetes. Diabetes Care 2010; 33: 1072-6.
12. Castle JR, Engle JM, El-Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010; 33: 1282-7.
13. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012; 35: 2148-55.
14. Hovorka R. Artificial Pancreas Project at Cambridge 2013. Diabet Med 2015; 32: 987-92.
15. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013; 36: 1851-8.
16. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368: 824-33.
17. Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care 2014; 37: 2310-6.
18. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014; 371: 313-25.
19. Haidar A, Legault L, Matteau-Pelletier L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: An open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2015; 3: 595-604.
20. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: Three-center randomized crossover study. Diabetes Care 2014; 37: 1931-7.
21. Nimri R, Muller I, Atlas E, et al. MDLogic overnight control for 6 weeks of home use in patients with type 1 diabetes: Randomized crossover trial. Diabetes Care 2014; 37: 3025-32.
22. Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: A 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol 2014; 2: 701-9.
23. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: A freeliving, randomized clinical trial. Diabetes Care 2014; 37: 1204-11.
24. Leelarathna L, Dellweg S, Mader JK, et al. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: A randomised crossover study protocol. BMJ Open 2014; 49: e006075.
25. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensoraugmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: A randomized clinical trial. JAMA 2013; 310: 1240-7.
26. Buckingham BA, Raghinaru D, Cameron F, et al. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care 2015; 38: 1197-204.
27. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014; 37: 1789-96.
28. Ly TT, Roy A, Grosman B, et al. Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 2015; 38: 1205-11.
29. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: An open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015; 3: 17-26.